Fidson Healthcare Plc Approves N3.6 Billion Dividend, Posts Record Revenue

Shareholders of Nigeria's largest pharmaceutical company, Fidson Healthcare Plc, have approved a dividend payout of ₦3.6 billion, equivalent to ₦1.50 per ordinary share. This decision came during the company's 27th Annual General Meeting held virtually on July 30, 2026. The approval follows a landmark year for Fidson, which recorded N119.06 billion in revenue for 2025, becoming the first Nigerian pharmaceutical company to exceed N100 billion in annual revenue. Chairman Fidelis Ayebae attributed this success to the dedication of the company's employees, shareholder confidence, and a robust long-term growth strategy. Ayebae also expressed gratitude to the Nigerian government for implementing policies that support local manufacturers and enable them to meet demand at affordable prices. The company is making significant strategic investments in expansion projects, aiming to become the most sophisticated and largest pharmaceutical manufacturing company in Sub-Saharan Africa upon completion. Managing Director Biola Adebayo emphasized the company's commitment to sustained growth through innovation, manufacturing excellence, and strategic investments, focusing on deepening manufacturing capabilities, expanding its product portfolio, and increasing market penetration.

“

We recorded revenue of ₦119.06 billion, becoming the first pharmaceutical company in Nigeria to surpass the ₦100 billion annual revenue milestone. This achievement reflects the dedication of our people, the confidence of our shareholders, and the effectiveness of our long-term growth strategy.